Skip to main content
Erschienen in: Medical Oncology 2/2010

01.06.2010 | Original Paper

Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

verfasst von: Bülent Karagöz, Oğuz Bilgi, Ahmet Alacacıoğlu, Alpaslan Özgün, Özkan Sayan, Alev Akyol Erikçi, Emin Gökhan Kandemir

Erschienen in: Medical Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment. Methods In this retrospective study, 46 postmenopausal women (20 with tmx and 26 with anastrazole) with breast cancer who received adjuvant hormone therapy were enrolled. The biochemical and complete blood count (CBC) parameters were documented before hormone treatment start and after 1 year. Results The lymphocyte count was higher after tmx use, but not anastrazole. Total white blood cells were increased both after 1-year tmx and anastrazole using. Mean platelet volume (MPV) increased after tmx use (8.2 ± 0.94–8.97 ± 0.97; P: 0.041), while it was not different after anastrazole use (7.96 ± 1.08–7.89 ± 0.99; P: 0.585). Other platelet parameters did not alter with tmx or anastrazole treatment. Conclusion We found increased MPV after tmx treatment, but did not after anastrazole treatment. The advanced studies which explore biological significance of high MPV in breast cancer patients used endocrine therapy, should be established.
Literatur
1.
Zurück zum Zitat O’Regan RM, Gradishar WJ. Selective estrogen-receptor modulators in 2001. Oncology (Williston Park). 2001;15:1177–90. O’Regan RM, Gradishar WJ. Selective estrogen-receptor modulators in 2001. Oncology (Williston Park). 2001;15:1177–90.
4.
Zurück zum Zitat Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881–94.PubMed Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881–94.PubMed
6.
7.
Zurück zum Zitat Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi:10.1016/S1470-2045(07)70385-6.CrossRefPubMed Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi:10.​1016/​S1470-2045(07)70385-6.CrossRefPubMed
9.
Zurück zum Zitat Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32:443–60. doi:10.1016/0049-3848(83)90255-4.CrossRefPubMed Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32:443–60. doi:10.​1016/​0049-3848(83)90255-4.CrossRefPubMed
11.
Zurück zum Zitat Muscari A, Puddu GM, Cenni A, Silvestri MG, Giuzio R, Rosati M, Santoro N, Bianchi G, Magalotti D, Zoli M. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res 2008 (in press). Muscari A, Puddu GM, Cenni A, Silvestri MG, Giuzio R, Rosati M, Santoro N, Bianchi G, Magalotti D, Zoli M. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res 2008 (in press).
14.
Zurück zum Zitat Ranganath LR, Christofides J, Semple MJ. Increased mean platelet volume after oestrogen replacement therapy. Ann Clin Biochem. 1996;33(Pt 6):555–60.PubMed Ranganath LR, Christofides J, Semple MJ. Increased mean platelet volume after oestrogen replacement therapy. Ann Clin Biochem. 1996;33(Pt 6):555–60.PubMed
Metadaten
Titel
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer
verfasst von
Bülent Karagöz
Oğuz Bilgi
Ahmet Alacacıoğlu
Alpaslan Özgün
Özkan Sayan
Alev Akyol Erikçi
Emin Gökhan Kandemir
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9191-2

Weitere Artikel der Ausgabe 2/2010

Medical Oncology 2/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.